• 1. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168

Research Brief on 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester (CAS: 1261599-72-7)

The compound 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester (CAS: 1261599-72-7) has recently garnered attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This research brief aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

Recent studies have highlighted the significance of 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester as a key intermediate in the synthesis of novel bioactive molecules. The presence of both nitro and trifluoromethyl groups in its structure enhances its reactivity and makes it a valuable building block for the development of pharmaceuticals targeting various diseases, including cancer and infectious diseases.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the compound's role as a precursor in the synthesis of kinase inhibitors. The study demonstrated that derivatives of 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester exhibited potent inhibitory activity against specific tyrosine kinases, which are implicated in cancer progression. The findings suggest that this compound could serve as a scaffold for designing next-generation kinase inhibitors with improved selectivity and efficacy.

Another notable research effort, documented in Bioorganic & Medicinal Chemistry Letters, investigated the antimicrobial properties of 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester derivatives. The study revealed that certain modifications to the ester moiety resulted in compounds with significant activity against drug-resistant bacterial strains. This underscores the compound's potential in addressing the growing challenge of antibiotic resistance.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester. A 2022 paper in Organic Process Research & Development detailed a scalable and cost-effective synthetic route, emphasizing green chemistry principles. The improved methodology not only enhances yield but also reduces environmental impact, aligning with the pharmaceutical industry's sustainability goals.

In conclusion, 5-Nitro-4'-(trifluoromethyl)biphenyl-2-carboxylic acid ethyl ester (CAS: 1261599-72-7) represents a versatile and promising compound in chemical biology and drug development. Its applications span from kinase inhibition to antimicrobial activity, and ongoing research continues to uncover its full potential. Future studies are expected to explore its utility in other therapeutic areas and further refine its synthetic pathways for industrial-scale production.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)